Loomis Sayles & Co. L P Purchases 393,997 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Loomis Sayles & Co. L P grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 33.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,575,349 shares of the biopharmaceutical company's stock after buying an additional 393,997 shares during the quarter. Regeneron Pharmaceuticals makes up about 121.2% of Loomis Sayles & Co. L P's investment portfolio, making the stock its 17th biggest position. Loomis Sayles & Co. L P owned 1.43% of Regeneron Pharmaceuticals worth $1,122,168,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Willner & Heller LLC raised its holdings in Regeneron Pharmaceuticals by 3.9% during the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after purchasing an additional 15 shares during the last quarter. OLD Second National Bank of Aurora lifted its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after buying an additional 15 shares during the period. Rakuten Securities Inc. increased its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after buying an additional 15 shares during the period. Finally, Manchester Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after buying an additional 18 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded up $1.53 during midday trading on Friday, reaching $637.36. The company's stock had a trading volume of 805,912 shares, compared to its average volume of 673,409. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $629.02 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock's 50 day simple moving average is $683.88 and its 200 day simple moving average is $800.34. The firm has a market capitalization of $69.68 billion, a PE ratio of 16.65, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the prior year, the business earned $11.86 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on REGN. Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. Finally, Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.